Lonza : Proxel ® LS Preservative Wins Technology Innovation Award from Ringier
June 07, 2017 at 11:05 am EDT
Share
Allendale, NJ (USA), 7 June 2017 - Lonza, a world leader and supplier of biocides, has been awarded the 2017 Ringier Technology Innovation Award for Proxel LS Preservative. The Ringier Technology Innovation Award for the coatings industry is a professional award in China that recognizes products or technologies contributing to environmental protection and sustainable development. This Lonza biocide was one of 9 winners in the additives category.
Proxel LS Preservative is the next-generation wet-state preservation product that offers MIT-free broad spectrum performance at dosages that do not invoke the EUH208 allergen phrase. This next generation preservative is designed to address the challenging global regulatory requirements while providing robust protection. Proxel LS Preservative is also expected to be in line with China's upcoming green label regulation proposal.
In accepting the award at a ceremony on 24 May 2017 in Shanghai (CN), Sandy Huang, Business Director of Coatings and Composites, Lonza China, said: 'We are committed to the development of new actives and formulations to align with the ever changing stringent global regulations. Guided by market demands, we collaborate with our customers to continue to innovate and bring new products to the market.'
Lonza Group Ltd. published this content on 07 June 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 07 June 2017 15:05:27 UTC.
Original documenthttp://www.lonza.com/about-lonza/media-center/news/Tensid/2017-06-07-14-24-English.aspx
Public permalinkhttp://www.publicnow.com/view/B631D84BA08E2F631854A45B4A25FAC1CF52A3BD
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients;
- small molecule drug substances (13.2%);
- technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%);
- other (2.8%).
Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).